Vertex Progresses With Kalydeco

October 8, 2013
Vertex Pharmaceuticals launched Kalydeco, a breakthrough drug for cystic fibrosis patients with at least one G551D gating mutation in 2012. The company recently submitted an sNDA to get the drug approved for CF patients with at least one non-G551D gating mutation, as well as EU marketing applications for the drug.